**Table 1** Demographic and laboratory characteristics of patients using levetiracetam

|  |  |
| --- | --- |
| **Age**  | 10.93±3.74 (4-17) years |
| **Sex n (%)****Male** **Female**  | 16 (53.33%)14 (46.7%)  |
| **Seizure type n (%)****Focal** **Generalised** | 13 (43.3%)17 (56.7%) |
| **EEG n (%)****Normal** **Abnormal** **Focal epileptiform discharges** **Generalised epileptiform discharges** |  6 (20 %)0 (0%)13 (43.3%)11 (36.7%) |
| **Cranial magnetic resonans imaging n (%)****Normal** **Abnormal**  | 25 (83.3%)5 (16.7%) |

  **Table 2** Comparison of ECG parameters before and after treatment with levetiracetam

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Pretreatment** **Mean**±**SD** **(Min–Max)**  | **Posttreatment 6.months** **Mean**±**SD** **(Min–Max)**  | ***P*  value** |
| **PR interval (sec.)**  | 0.136±0.019 (0.11-0.18) | 0.131±0.015 (0.12-0.16) | 0.271 |
| **QTc (sec.)** | 0.411±0.023 (0.4-0.5) | 0.402±0.022 (0.35-0.45)  | 0.127 |
| **Heart rate (beat/min.)**  | 94.87±12.12(60-115) | 92.27±9 (71-107)  | 0.257 |

**Table 3** Comparison of ECG parameters before and after treatment with levetiracetam between genders

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Sex** | **Pretreatment** **Mean**±**SD** **(Min–Max)** |  | **Posttreatment 6.months** **Mean**±**SD** **(Min–Max)** |  |
| **Female**  | **Male**  | ***P*  value****(Pre)** | **Female**  | **Male**  | ***P*  value****(Post)** |
| **PR interval (sec.)**  | 0.130±0.015 (0.12-0.16) | 0.140±0.22(0.11-0.18) | 0.225 | 0.137±0.0149(0.12-0.16) | 0.131±0.015(0.12-0.16) | 0.963  |
| **QTc (sec.)** | 0.414±0.024 (0.4-0.5) | 0.408±0.023(0.4-0.5) | 0.702 | 0.403±0.018 (0.38-0.44)  | 0.40±0.025(0.35-0.45) | 0.815 |
| **Heart rate (beat/min.)**  | 96.57±10.70 (80-115) | 93.37±13.41(60-110) | 0.481 | 92.36±8.168 (75-107)  | 92.19±9.94 (71-105) | 0.474 |

**Table 4** Comparison of ECG parameters before and after treatment with levetiracetam between seizure types

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Seizure** **Type**  | **Pretreatment** **Mean**±**SD** **(Min–Max)** |  | **Posttreatment 6.months** **Mean**±**SD** **(Min–Max)** |  |
| **Focal**  | **Generalized**  | ***P* value****(Pre)** | **Focal** | **Generalized**  | ***P* value****(Post)** |
| **PR interval (sec.)**  | 0.140±0.018 (0.12-0.16) | 0.132±0.020(0.11-0.18) | 0.189 | 0.126±0.012(0.12-0.16) | 0.134±0.016(0.12-0.16) | 0.081 |
| **QTc (sec.)** | 0.409±0.023 (0.4-0.5) | 0.412±0.024(0.4-0.5) | 0.623 | 0.396±0.017 (0.38-0.42)  | 0.406±0.024(0.35-0.45) | 0.966 |
| **Heart rate (beat/min.)**  | 90.23±12.61 (60-107) | 98.41±10.79(78-115) | 0.066 | 92.85±6.90 (85-107)  | 91.82±10.52 (71-105) | 0.764 |